Original articleA novel approach to prevent endothelial hyperpermeability: The Crataegus extract WS® 1442 targets the cAMP/Rap1 pathway
Highlights
► The Crataegus extract WS® 1442 protects against endothelial hyperpermeability in vivo and in vitro. ► WS® 1442 inhibits detrimental effects of thrombin on adherens junctions, the F-actin cytoskeleton, and the contractile apparatus. ► Mechanistically, WS® 1442 blocks the thrombin-induced barrier-disrupting calcium/PKC/RhoA signaling. ► Concurrently, WS® 1442 activates the barrier-stabilizing cAMP/Epac/Rap1 pathway. ► WS® 1442 opens a novel pharmacological approach to treat hyperpermeability-associated diseases.
Introduction
Endothelial hyperpermeability, i.e. a compromised endothelial barrier function, and the subsequent formation of edema are hallmarks of many severe disorders, such as atherosclerosis [1], asthma [2], sepsis [3], or heart failure [4]. In the last years, significant progress has been made in elucidating the mechanisms involved in endothelial barrier dysfunction. Focusing on paracellular permeability, barrier destabilization is described as the formation of minute interendothelial gaps [5]. These gaps are mainly regulated by subcellular systems that form adhesive cell–cell contacts (e.g. adherens junctions/VE-cadherin) and exhibit retraction forces (e.g. the contractile apparatus/actomyosin). The function of these systems has been extensively characterized and the signaling mechanisms governing their operating status have been analyzed in detail [5]. Nevertheless, this profound knowledge is as yet not reflected in the implementation of new drugs that counteract barrier dysfunction by tackling these signaling systems. The search for novel pharmacological approaches is an ongoing need [6].
We proposed that the herbal remedy WS® 1442 prevents endothelial hyperpermeability and investigated its action on barrier dysfunction in vitro and in vivo. WS® 1442, a standardized hawthorn (Crataegus spp.) special extract, is widely used for the treatment of congestive heart failure according to the New York Heart Association (NYHA) functional class II because of its beneficial direct actions on the heart [7], [8]. Its efficacy and safety have been verified in several double-blind randomized clinical trials [9], [10], [11]. Crataegus extracts are among the most frequently used herbal medicinal products world-wide. The acceptance of herbal remedies—whether they are approved/registered drugs or nutrition supplements—is often ideologically influenced and, moreover, their use is controversially discussed due to the extract's inherent multi-component feature (polypharmacology) and the frequently missing in-depth mechanistic analysis. We set out to address this issue by coming up with a profound explanation for the action of WS® 1442: We provide a comprehensive insight into the underlying mechanisms affected by this extract in the human endothelium.
Section snippets
Materials
The Crataegus special extract WS® 1442 was kindly provided by the company Dr. Willmar Schwabe GmbH & Co. KG (Karlsruhe, Germany). Thrombin and GGTI-298 were from Sigma-Aldrich (Taufkirchen, Germany), adenosine-3′,5′-monophosphorothioate triethylammonium salt Rp-isomer (cAMPS-Rp), 8-bromoadenosine-3′,5′-cyclic monophosphate sodium salt (8-Br-cAMP), and forskolin were from Biotrend (Cologne, Germany). 8-(4-Chlorophenylthio)-2′-O-methyladenosine-3′,5′-cyclic mono-phosphate sodium salt
WS® 1442 protects endothelial barrier function in vivo and in vitro
The extravasation of the macromolecule FITC–dextran from postcapillary venules of the mouse cremaster muscle was monitored via intravital fluorescence microscopy. Histamine was used as permeability-increasing factor. WS® 1442 (100 μg, applied i.a. 30 min prior to histamine) clearly abrogated the histamine-induced dextran extravasation and maintained endothelial barrier function (Figs. 1A/B). In vitro, macromolecular permeability through an HMEC-1 monolayer was assessed. WS® 1442 (30 min
Discussion
In the present study, we introduce WS® 1442 as a novel endothelial barrier-protecting approach, both in vitro and in vivo. WS® 1442 was found to beneficially act on (1) adhesion junction stability (VE-cadherin morphology, internalization, Tyr731 phosphorylation), (2) actin stress fiber formation (F-actin distribution and content), and (3) endothelial contraction (phospho-myosin light chain distribution and content). Thus, WS® 1442 influences pivotal systems that tightly regulate endothelial
Conclusion
We have shown that the herbal drug WS® 1442 effectively protects against endothelial barrier dysfunction by its action on key determinants of endothelial permeability (adherens junctions, actin cytoskeleton, and contractile apparatus). Mechanistically, WS® 1442 inhibits the barrier-destabilizing calcium/PKC/Rho signaling and activates the barrier-stabilizing cAMP/Epac1/Rap1 pathway. Thus, our study highlights WS® 1442 as a novel valuable approach for preventing endothelial hyperpermeability and
Disclosures
None.
Acknowledgments
This work was supported by the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft) [FU 691/7-1 to RF and AMV]. The extract WS® 1442 was kindly provided by the company Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany. MF, EAW, PB, and HA performed the research and analyzed the data. GJ contributed essential reagents. FK, SZ, AMV, and RF designed the study. RF wrote the paper.
References (31)
- et al.
Peripheral edema
Am J Med
(2002) - et al.
Targets for pharmacological intervention of endothelial hyperpermeability and barrier function
Vascul Pharmacol
(2002) Efficacy and safety of Crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure
Am Heart J
(2002)- et al.
HMEC-1: establishment of an immortalized human microvascular endothelial cell line
J Invest Dermatol
(1992) Applications for ROCK kinase inhibition
Curr Opin Cell Biol
(2008)- et al.
Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation
Exp Cell Res
(2007) Clinical efficacy of Crataegus extract WS 1442 in congestive heart failure NYHA class II
Phytomedicine
(2001)- et al.
Rac GTPase is a hub for protein kinase A and Epac signaling in endothelial barrier protection by cAMP
Microvasc Res
(2010) - et al.
Rho GTPases and the regulation of endothelial permeability
Vascul Pharmacol
(2002) Endothelial dysfunction in the pathogenesis of atherosclerosis
Int Angiol
(2002)
The bronchial microcirculation in asthma
Clin Exp Allergy
Endothelium function in sepsis
Inflamm Res
Regulation of endothelial junctional permeability
Ann N Y Acad Sci
Crataegus extract blocks potassium currents in guinea pig ventricular cardiac myocytes
Planta Med
Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently
J Cardiovasc Pharmacol
Cited by (29)
Inhibition of MRP4 alleviates sepsis-induced acute lung injury in rats
2019, International ImmunopharmacologyAsiatic acid stabilizes cytoskeletal proteins and prevents TNF-α-induced disorganization of cell-cell junctions in human aortic endothelial cells
2019, Vascular PharmacologyCitation Excerpt :Actin cytoskeleton is an important determinant of endothelial barrier function and proper regulation of the actin cytoskeleton is required to maintain the integrity of endothelial barrier [28]. The enhancement of peripheral cortical actin network has been associated with barrier protective effects of several agents including sphingosine-1-phosphate [29] and a standardized hawthorn extract known as WS®1442 [30]. We demonstrated that asiatic acid preserved peripheral F-actin filaments and partially suppressed TNF-α-induced stress fiber formation (Fig. 1).
Herbal Medications in Cardiovascular Medicine
2017, Journal of the American College of CardiologyCitation Excerpt :A vasodilating effect of hawthorn in both the coronary and the peripheral vessels has been described, and could directly influence NO levels in the endothelium and inhibit angiotensin-converting enzyme (88). It has also been claimed that hawthorn may have an antiatherosclerotic effect, reducing endothelial barrier dysfunction (89), inhibiting smooth muscle cell migration and proliferation after vessel injury, and inhibiting platelet aggregation (90,91). In addition, it has been suggested that hawthorn can inhibit cholesterol synthesis in the liver and lipid absorption in the intestine (92,93).
Hawthorn (Crataegus pinnatifida Bunge) leave flavonoids attenuate atherosclerosis development in apoE knock-out mice
2017, Journal of EthnopharmacologyCitation Excerpt :In clinical trials evaluating the efficacy of hawthorn, patients diagnosed with chronic heart failure (CHF) and categorised according to New York Heart Association (NYHA) classification (classes I to III), the leaf and flower extracts of hawthorn increased exercise tolerance and improved the symptoms of fatigue and shortness of breath (Pittler et al., 2008, 2003). A standardized extract of WS 1442 and LI 132 were used as an adjunctive treatment and shown benefit in symptom control and physiologic outcomes (Bubik et al., 2012; Rigelsky and Sweet, 2002). It was demonstrated that hawthorn fruits or their extracts were able to protect against development of atherosclerosis (Zhang et al., 2013, 2014).
Tumor necrosis factor reduces Plasmodium falciparum growth and activates calcium signaling in human malaria parasites
2016, Biochimica et Biophysica Acta - General SubjectsCitation Excerpt :Plasmodium infection remodels the cytoskeleton network in infected erythrocyte (IE) [4] and communication has been shown to occur by exosome-like vesicles sensitive to actin filaments and microtubule inhibitors, which are released into culture supernatant and provide means to respond to environmental changes [5]. Tumor necrosis factor (TNF) is a well-known pro-inflammatory cytokine involved in host immunological responses that elicit diverse cellular responses ranging from proliferation to activation of apoptosis (reviewed in [6–8] and inhibitors of TNF production reduced IE cytoadherence [9–10]. In mammalian cells, the biological activities of TNF are mediated by two distinct cell-surface receptors: tumour-necrosis factor receptor-1 or 2 (TNFR1 and TNFR2).
Distinct functions for Rap1 signaling in vascular morphogenesis and dysfunction
2013, Experimental Cell Research